| abstract |
The invention relates to a method for treating metastatic castration-resistant prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic castration-sensitive prostate cancer, non-metastatic castration-sensitive prostate cancer or localized high-risk prostate cancer in a male patient comprising orally administering a compound of formula (I) or a pharmaceutically acceptable salt thereof to a male patient in need of such treatment at a dose of from 30 to 480 mg per day in combination with (a) abiraterone acetate and (b) prednisone. |